Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Back to our regularly scheduled program

<< Previous

Bullboard Posts

Next >>

Comment by hmmmmmmmmon Jan 06, 2024 4:38pm

154 Views

Post# 35814038

RE:RE:RE:RE:RE:RE:Back to our regularly scheduled program

Nov 10 2022 48 patients enrolled.

Dec 14 2023 81 patients enrolled.

33 patients enrolled in the past 13 months.

2.54 patients per month.

150 minus the 81 patients enrolled = 69 patients needed to complete the Tigris trial.

69 divided 2.54 = 27 months.

That is why investors who actually look at real numbers see 2+ years ahead.

It's also why you are working so hard to try and sell your early trial stoppage tale.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale